COSCIENS Biopharma Inc. (CSCI) - Dilution Analysis

20-F filing | 3.2M shares outstanding

POS AM filing: This Post-Effective Amendment No. 6 to Form F-1 relates to the Registration Statement and terminates the offering of the securities pursuant to the Registration Statement in the United States.

POS AM filing: This post-effective amendment terminates the effectiveness of the registration statement and removes from registration any and all of such securities registered and remaining unsold under the Registration Statement.

POS AM filing: Post-Effective Amendment No. 1 to Form F-3 terminates the effectiveness of the Registration Statement and removes from registration any and all of such securities registered and remaining unsold under the Registration Statement.

POS AM filing: This post-effective amendment terminates the effectiveness of the registration statement and removes from registration any and all of such securities registered and remaining unsold under the registration statement.

20-F filing | 3.1M shares outstanding

POS AM filing: Aeterna Zentaris Inc. is offering up to 56,211 of its common shares issuable upon the exercise of warrants at an exercise price of $45.00, also issuing shares as part of arrangement.

POS AM filing: This prospectus relates to the disposition from time to time of up to 24,378 common shares of Aeterna Zentaris Inc. upon exercise of warrants.

POS AM filing: Aeterna Zentaris Inc. is offering 17,310 Common Shares, no par value, each with one right to purchase a Common Share under the Rights Plan. The company will not receive any proceeds from the sale of Common Shares by the selling shareholders.

20-F filing | 4.9M shares outstanding

F-1 filing: This F-1 filing relates to the issuance of Aeterna Zentaris New Warrants and the underlying common shares upon exercise of those warrants in connection with the acquisition of Ceapro Inc.

POS AM filing: Aeterna Zentaris Inc. is offering 97,521 of its Common Shares, no par value, each with one right to purchase a Common Share under their Rights Plan.

POS AM filing: Aeterna Zentaris Inc. is offering 69,241 of its Common Shares, no par value.

POS AM filing: Aeterna Zentaris Inc. is offering up to 224,845 common shares issuable upon the exercise of warrants at an exercise price of $11.25 per share. The warrants expire on July 7, 2025, and the company intends to use the proceeds from the exercise of the Common Warrants for general corporate purposes.

20-F filing | 4.9M shares outstanding

POS AM filing: This is a filing for common shares issuable upon the exercise of warrants at an exercise price per whole Common Share of $0.45.

POS AM filing: Aeterna Zentaris Inc. is offering 1,731,024 of its Common Shares, no par value, each with one right to purchase a Common Share under its Rights Plan. The company will not receive any proceeds from the sale of these shares by the selling shareholders.

POS AM filing: This summary highlights information presented in greater detail elsewhere in this prospectus and does not contain all the information you should consider before investing in our Common Shares.

20-F filing | 121.4M shares outstanding

POS AM filing: Aeterna Zentaris Inc. is offering 2,438,044 of its Common Shares, no par value.

POS AM filing: Aeterna Zentaris Inc. is offering up to 5,872,333 common shares issuable upon the exercise of warrants at an exercise price of $0.45 per share. The Common Warrants were exercisable upon issuance, and expire July 7, 2025.

POS AM filing: This prospectus relates to the disposition from time to time of up to 2,311,758 common shares issuable upon exercise of outstanding unregistered warrants previously issued by us in August 2020 which entitle the holders to purchase our Common Shares, at an exercise price of $0.47 per share, and which are currently exercisable until February 5, 2026.

POS AM filing: Aeterna Zentaris Inc. is offering up to 5,872,333 common shares issuable upon the exercise of warrants at an exercise price of $0.45 per share. The warrants are exercisable upon issuance and expire July 7, 2025.

POS AM filing: This prospectus relates to the disposition from time to time of up to 2,311,758 common shares, no par value per share of Aeterna Zentaris Inc. These Common Shares may be acquired, or have been acquired, upon exercise of outstanding unregistered warrants previously issued by us in August 2020 which entitle the holders to purchase our Common Shares, at an exercise price of $0.47 per share, and which are currently exercisable until February 5, 2026.

40-F filing | 62.7M shares outstanding

F-3 filing: This F-3 filing relates to the disposition from time to time by the Selling Shareholders identified in this prospectus of up to 1,651,034 common shares, no par value per share, of Aeterna Zentaris Inc. These Common Shares may be acquired upon exercise of outstanding unregistered warrants previously issued by us in February 2021 as underwriter consideration.

POS AM filing: This summary highlights information presented in greater detail elsewhere in this prospectus.

F-1 filing: This F-1 filing relates to the disposition from time to time by the Selling Shareholders of up to 10,190,859 common shares of Aeterna Zentaris Inc., which includes shares that may be acquired upon exercise of outstanding unregistered warrants.

F-1 filing: Aeterna Zentaris Inc. is offering units, or the "Units", with each Unit consisting of (i) one common share and (ii) one warrant to purchase Common Share, and pre-funded units, or the "Pre-Funded Units", with each Pre-Funded Unit consisting of (i) a pre-funded warrant to purchase one Common Share, or a "Pre-Funded Warrant," and (ii) one Common Warrant.

F-1 filing: This prospectus relates to the disposition from time to time of up to 6,177,174 common shares of Aeterna Zentaris Inc.

20-F filing | 20.0M shares outstanding